Are you curious about the effectiveness and success rate of HyProCure? You’re not alone. HyProCure has been FDA cleared since 2004 and CE marked since 2006. This is a procedure that has been performed in tens of thousands of pediatric and adult patients. HyProCure is the “go-to” sinus tarsi stent for leading foot surgeons in over 60 countries!
HyProCure is proven to:
- Decrease strain on the posterior tibial tendon
- Decrease tibialis posterior nerve strain/elongation
- Decrease pressures in the tarsal tunnel & porta pedis
- Decrease strain on the plantar fascia
- Decrease forces acting on the medial column
- Normalize both sagittal and transverse plane displacement
- Restore and maintain navicular height
- Normalize plantar forefoot pressure
Did you know that HyProCure:
- Is classified as a Type II, non-arthroereisis sinus tarsi stent
- Stabilizes the talocalcaneal joint entrance of the canalis tarsi to re-establish the talotarsal joint center of axis
- Rebalances forces acting on the tarsal mechanism, reduces the forces acting on medial column of the foot
- Reduces strain to the tibialis posterior tendon by a mean of 51%
- Reduces strain to the medial band of the plantar fascia by a mean of 33%
- Decreases strain on the tibialis posterior nerve by a mean of 15%
- Decreases the pressures within the tarsal tunnel by a mean of 34% and the porta pedis by a mean of 38%
- Prevents navicular sag/drop by 26%
- Normalizes plantar foot pressures – prospective study
- Restores both transverse and sagittal plane talotarsal joint displacement deformities
- Has only a 6% permanent removal rate in adults as a stand-alone procedure – retrospective analysis
- Has only a 4% removal rate in pediatric and adult patients – prospective study
- Is a superior option to realign the hindfoot over arch supports/foot orthotics
- Is a superior option in the treatment of pediatric talotarsal joint displacement
We invite you to learn more about the published studies on the safety and efficacy of HyProCure by reading our flipbook below.
